Avinger (AVGR) Misses Q3 EPS by 21c

Go back to Avinger (AVGR) Misses Q3 EPS by 21c

Avinger, Inc. Announces Third Quarter 2015 Results

November 5, 2015 4:09 PM EST

Received FDA Clearance for Pantheris

Accelerated Expansion of Installed Base of Lumivascular Platform

REDWOOD CITY, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported results for the third quarter ended September 30, 2015.

Recent Highlights

Received 510(k) clearance from the United States Food and Drug Administration (FDA) to commence U.S. commercialization of Pantheris, the first-ever image-guided atherectomy device using... More

Avinger, Inc. to Present at Upcoming Investor Conferences

November 3, 2015 4:05 PM EST

REDWOOD CITY, Calif., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced the Company will be participating in two upcoming investor conferences.

Avinger's management is scheduled to present at the Stephens Fall Investment Conference in New York City, NY on... More